About ZIOPHARM Oncology (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ZIOP
- CUSIP: 98973P10
- Web: www.ziopharm.com
Capitalization:- Market Cap: $810.61 million
- Outstanding Shares: 140,632,000
Average Prices:- 50 Day Moving Avg: $6.18
- 200 Day Moving Avg: $6.22
- 52 Week Range: $4.84 - $7.88
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.91
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $6.39 million
- Price / Sales: 126.55
- Book Value: ($0.46) per share
- Price / Book: -12.50
Profitability:- EBITDA: ($48,700,000.00)
- Net Margins: -789.28%
- Return on Assets: -45.35%
Debt:- Current Ratio: 7.83%
- Quick Ratio: 7.83%
Misc:- Average Volume: 1.05 million shs.
- Beta: 1.64
- Short Ratio: 42.97
Frequently Asked Questions for ZIOPHARM Oncology (NASDAQ:ZIOP)
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) posted its quarterly earnings results on Monday, July, 31st. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. The firm's revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.01) EPS. View ZIOPHARM Oncology's Earnings History.
When will ZIOPHARM Oncology make its next earnings announcement?
Where is ZIOPHARM Oncology's stock going? Where will ZIOPHARM Oncology's stock price be in 2017?
3 brokers have issued 12 month price objectives for ZIOPHARM Oncology's stock. Their forecasts range from $10.00 to $23.00. On average, they expect ZIOPHARM Oncology's share price to reach $16.50 in the next twelve months. View Analyst Ratings for ZIOPHARM Oncology.
Are investors shorting ZIOPHARM Oncology?
ZIOPHARM Oncology saw a increase in short interest in September. As of September 29th, there was short interest totalling 33,322,518 shares, an increase of 2.7% from the September 15th total of 34,255,870 shares. Based on an average daily volume of 968,494 shares, the days-to-cover ratio is currently 34.4 days. Approximately 26.1% of the shares of the stock are short sold.
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include NovoCure Limited (NVCR), AnaptysBio (ANAB), Radius Health (RDUS), Five Prime Therapeutics (FPRX), MyoKardia (MYOK), Ascendis Pharma A/S (ASND), Clinigen Group PLC (CLIN), Dynavax Technologies Corporation (DVAX), Acorda Therapeutics (ACOR), Sangamo Therapeutics (SGMO), Epizyme (EPZM), Lexicon Pharmaceuticals (LXRX), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), REGENXBIO (RGNX), Athenex (ATNX) and Omeros Corporation (OMER).
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the folowing people:
- Laurence James Neil Cooper M.D., Ph.D., Chief Executive Officer
- Kevin G. Lafond CPA, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
- Caesar J. Belbel, Chief Operating Officer, Executive Vice President, Chief Legal Officer, Secretary
- Francois Lebel M.D., Executive Vice President - Research and Development and Chief Medical Officer
- David M. Mauney M.D., Executive Vice President, Chief Business Officer
- Lynn Ferrucci, Senior Vice President - Human Resources, Facilities and Administration
- David Connolly, Vice President - Corporate Communications and Investor Relations
- Murray Brennan M.D., Non-Executive Lead Independent Director
- Randal J. Kirk, Director
- James A. Cannon, Independent Director
How do I buy ZIOPHARM Oncology stock?
Shares of ZIOPHARM Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZIOPHARM Oncology's stock price today?
One share of ZIOPHARM Oncology stock can currently be purchased for approximately $5.75.
MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ZIOPHARM Oncology (NASDAQ:ZIOP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $16.50 (186.96% upside) |
Consensus Price Target History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Analysts' Ratings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/1/2017 | HC Wainwright | Set Price Target | Buy | $10.00 | Medium |  |
| 2/28/2017 | Griffin Securities | Reiterated Rating | Buy | $23.00 | N/A | |
| 1/12/2017 | J P Morgan Chase & Co | Reiterated Rating | Hold | | N/A | |
| 8/10/2016 | Wells Fargo & Company | Upgrade | Underperform -> Market Perform | | N/A | |
| 7/18/2016 | Mizuho | Reiterated Rating | Neutral | $7.00 -> $5.00 | N/A | |
| 6/2/2016 | Raymond James Financial, Inc. | Initiated Coverage | Market Perform | | N/A | |
(Data available from 10/19/2015 forward)
Earnings History for ZIOPHARM Oncology (NASDAQ:ZIOP)Earnings History by Quarter for ZIOPHARM Oncology (NASDAQ ZIOP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | | | | | | | |
| 7/31/2017 | Q2 2017 | ($0.13) | ($0.13) | $1.66 million | $1.60 million | View | N/A | |
| 5/1/2017 | Q1 2017 | ($0.12) | ($0.15) | $1.71 million | $1.60 million | View | Listen | |
| 11/9/2016 | Q3 2016 | ($0.11) | ($0.11) | $1.45 million | $1.60 million | View | N/A | |
| 8/9/2016 | Q216 | ($0.11) | ($1.01) | $1.52 million | $1.70 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.08) | ($0.09) | $1.89 million | $1.97 million | View | N/A | |
| 2/24/2016 | Q4 | ($0.07) | ($0.07) | $1.82 million | $1.92 million | View | N/A | |
| 11/2/2015 | Q315 | ($0.13) | ($0.14) | $1.19 million | $1.90 million | View | N/A | |
| 8/10/2015 | Q2 | ($0.22) | ($0.11) | $57.70 million | $0.27 million | View | N/A | |
| 5/7/2015 | | ($0.13) | ($0.10) | $0.20 million | $0.30 million | View | N/A | |
| 2/26/2015 | Q414 | ($0.14) | ($0.09) | $420.00 million | $0.34 million | View | N/A | |
| 10/30/2014 | Q314 | ($0.12) | ($0.06) | $0.20 million | $0.63 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.17) | ($0.06) | $7.50 million | $0.20 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.10) | ($0.10) | $0.20 million | $0.20 million | View | N/A | |
| 3/3/2014 | Q413 | ($0.15) | ($0.09) | $0.20 million | $0.20 million | View | N/A | |
| 10/22/2013 | Q313 | ($0.17) | ($0.20) | | $0.20 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.24) | ($0.22) | $0.20 million | $0.20 million | View | N/A | |
| 3/18/2013 | Q4 2012 | ($0.29) | ($0.48) | $0.17 million | $0.20 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.28) | ($0.28) | $0.20 million | $0.20 million | View | N/A | |
| 8/2/2012 | | ($0.23) | ($0.29) | | | View | N/A | |
| 5/3/2012 | | ($0.22) | ($0.25) | | | View | N/A | |
| 2/29/2012 | | ($0.23) | ($0.24) | | | View | N/A | |
| 11/3/2011 | | ($0.28) | ($0.01) | | | View | N/A | |
| 8/1/2011 | | ($0.23) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ZIOPHARM Oncology (NASDAQ:ZIOP)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.09) | ($0.09) | ($0.09) |
| Q2 2017 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q3 2017 | 1 | ($0.09) | ($0.09) | ($0.09) |
(Data provided by Zacks Investment Research)
Dividend History for ZIOPHARM Oncology (NASDAQ:ZIOP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ZIOPHARM Oncology (NASDAQ:ZIOP)Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 41.94%
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/4/2015 | Murray Brennan | Director | Sell | 40,000 | $9.70 | $388,000.00 | |
| 2/9/2015 | Randal J Kirk | Director | Buy | 1,440,000 | $8.75 | $12,600,000.00 | |
| 10/29/2013 | Randal J Kirk | Director | Buy | 2,857,143 | $3.50 | $10,000,000.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for ZIOPHARM Oncology (NASDAQ:ZIOP)
Latest Headlines for ZIOPHARM Oncology (NASDAQ:ZIOP)
| Source: |
|
| Date | Headline |
|---|
 | The case for Ziopharm Oncology, Inc. - Motley Fool
www.fool.com - October 18 at 11:02 AM |
 | ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the ... - GlobeNewswire (press release)
globenewswire.com - October 17 at 9:32 AM |
 | Watch These 8 Huge Put Purchases In Friday Trade - Benzinga
www.benzinga.com - October 13 at 10:34 AM |
 | Breakfast Technical Briefing on Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and ZIOPHARM Oncology
www.bizjournals.com - October 12 at 10:35 AM |
 | Breakfast Technical Briefing on Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and ... - PR Newswire (press release)
www.prnewswire.com - October 12 at 10:35 AM |
 | ZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : October 11, 2017
finance.yahoo.com - October 11 at 9:50 AM |
| ZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 6 at 1:08 PM |
| ETFs with exposure to ZIOPHARM Oncology, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 1:08 PM |
 | ZIOPHARM Oncology Inc (ZIOP) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 30 at 2:46 AM |
| ZIOPHARM Oncology Appoints David Mauney, MD, as Executive Vice President and Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - September 29 at 10:26 PM |
| ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer
feeds.benzinga.com - September 28 at 5:43 PM |
| ZIOPHARM Oncology Inc (ZIOP) Expected to Post Quarterly Sales of $1.59 Million
www.americanbankingnews.com - September 19 at 1:40 PM |
| -$0.13 EPS Expected for ZIOPHARM Oncology Inc (ZIOP) This Quarter
www.americanbankingnews.com - September 17 at 4:24 AM |
 | ZIOPHARM Oncology (ZIOP) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 15 at 11:51 AM |
 | ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
www.nasdaq.com - September 5 at 8:38 PM |
| ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 3:38 PM |
| ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 9:46 AM |
| ZIOPHARM Oncology Inc (ZIOP) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 5 at 2:40 AM |
| ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit - GlobeNewswire (press release)
globenewswire.com - September 2 at 1:29 AM |
| ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit ... - Nasdaq
www.nasdaq.com - September 1 at 11:41 AM |
| ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit
finance.yahoo.com - September 1 at 11:41 AM |
| Brokerages Anticipate ZIOPHARM Oncology Inc (ZIOP) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - August 29 at 4:20 PM |
| ZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bullish Manner : ZIOP-US : August 29, 2017
finance.yahoo.com - August 29 at 10:04 AM |
 | Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock
www.zacks.com - August 28 at 8:01 AM |
| Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock
www.zacks.com - August 28 at 8:01 AM |
| ZIOPHARM Oncology, Inc. – Value Analysis (NASDAQ:ZIOP) : August 19, 2017
finance.yahoo.com - August 19 at 9:08 AM |
| -$0.13 Earnings Per Share Expected for ZIOPHARM Oncology Inc (NASDAQ:ZIOP) This Quarter
www.americanbankingnews.com - August 11 at 2:36 PM |
| ZIOPHARM Oncology Inc (ZIOP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 11:08 AM |
| Intrexon (XON) Q2 Loss Narrower than Expected, Revenues Miss - Nasdaq
www.nasdaq.com - August 11 at 9:25 AM |
| ZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bullish Manner : ZIOP-US : August 8, 2017
finance.yahoo.com - August 8 at 8:32 AM |
| Sky's The Limit For Ziopharm - Seeking Alpha
seekingalpha.com - August 4 at 10:17 AM |
| ZIOPHARM Oncology's (ZIOP) CEO Laurence Cooper on Q2 2017 ... - Seeking Alpha
seekingalpha.com - August 2 at 9:02 AM |
| ZIOPHARM Oncology, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 1 at 8:03 AM |
| Ziopharm reports 2Q loss
finance.yahoo.com - August 1 at 8:03 AM |
| Edited Transcript of ZIOP earnings conference call or presentation 31-Jul-17 8:30pm GMT
finance.yahoo.com - August 1 at 8:03 AM |
| ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Posts Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - July 31 at 9:10 PM |
| Head-To-Head Survey: Otonomy (OTIC) and ZIOPHARM Oncology (ZIOP)
www.americanbankingnews.com - July 31 at 8:26 PM |
| ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - July 27 at 5:59 PM |
| ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate ...
www.nasdaq.com - July 25 at 8:55 AM |
| Brokerages Expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 24 at 11:06 AM |
| ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET
feeds.benzinga.com - July 24 at 7:38 AM |
| ZIOPHARM Oncology Inc (ZIOP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 17 at 11:29 AM |
| Pfizer's Mylotarg Recommended by FDA Advisory Committee
www.zacks.com - July 13 at 11:31 AM |
| ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + ... - GlobeNewswire (press release)
globenewswire.com - June 30 at 2:34 AM |
 | Ziopharm Oncology (ZIOP) Reports Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma
www.streetinsider.com - June 29 at 8:15 AM |
| Bullish On Ziopharm
seekingalpha.com - June 22 at 2:54 PM |
| Mid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge
feeds.benzinga.com - June 20 at 3:55 PM |
| ZIOPHARM Oncology (ZIOP) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 12 at 3:15 PM |
| Ziopharm Oncology (ZIOP) Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at ASCO
www.streetinsider.com - June 6 at 3:16 AM |
| ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 2 at 8:17 AM |
ZIOPHARM Oncology (ZIOP) Chart for Thursday, October, 19, 2017
